What Information is Available?

Ongoing research in the world today constantly documents the link between sleep and health analomies. It is becoming apparent that human systems rely on solid sleep patterns to reset themselves and promote healthy bodily functions.

From time to time Louisiana Sleep Foundation will post health articles discussing the affects of chronic sleep disorders. Please take a moment to browse these documents. If you have any questions or comments about any of this literature, please contact us. We will be happy to set up an appointment to discuss this with you.

Recent Articles

Obstructive Sleep Apnea (OSA) and Children, October 2, 2004

OSASnoring and obstructive sleep apnoea in children: why should we treat?

Gozal D, O’Brien LM.

Kosair Children’s Hospital Research Institute, Department of Pediatrics, University of Louisville School of Medicine, USA. david.gozal@louisville.edu

Frequent and loud snoring is a very frequent condition in prepubertal children affecting approximately 10% of all 2-8 year old children. If polysomnographical evaluations are performed in these snoring children, approximately 10% will be diagnosed with obstructive sleep apnoea (OSA). The pathophysiology of OSA in children is still poorly understood. Indeed, while adenotonsillar hypertrophy is certainly a major contributor to OSA, other factors need to be implicated for OSA to develop. In recent years, it has become apparent that OSA and snoring are not as innocuous as previously thought. Indeed, epidemiological and pre-post treatment analyses have identified substantial morbidities that primarily affect cardiovascular and neurobehavioural systems, namely pulmonary hypertension, systemic elevation of arterial blood pressure, nocturnal enuresis, reduced somatic growth, behavioural problems that resemble attention deficit-hyperactivity disorder, as well as learning and cognitive deficits. These problems are associated with marked increases in healthcare-related costs. More importantly, if timely diagnosis and intervention are not implemented, some of these morbid complications may not be completely reversible, leading to long-lasting residual consequences.

PMID: 14980299 [PubMed – in process]

Hypertension independently associated with OSA (JAMA), May 14, 2003

See full article at JAMA

OSA, obesity and hypertension, January 1, 2000

Obesity, sleep apnea, and hypertension.

Wolk R, Shamsuzzaman AS, Somers VK.

Mayo Clinic, Rochester, Minn, USA.

Obesity has a high and rising prevalence and represents a major public health problem. Obstructive sleep apnea (OSA) is also common, affecting an estimated 15 million Americans, with a prevalence that is probably also rising as a consequence of increasing obesity. Epidemiologic data support a link between obesity and hypertension as well as between OSA and hypertension. For example, untreated OSA predisposes to an increased risk of new hypertension, and treatment of OSA lowers blood pressure, even during the daytime. Possible mechanisms whereby OSA may contribute to hypertension in obese individuals include sympathetic activation, hyperleptinemia, insulin resistance, elevated angiotensin II and aldosterone levels, oxidative and inflammatory stress, endothelial dysfunction, impaired baroreflex function, and perhaps by effects on renal function. The coexistence of OSA and obesity may have more widespread implications for cardiovascular control and dysfunction in obese individuals and may contribute to some of the clustering of abnormalities broadly defined as the metabolic syndrome. From the clinical and therapeutic perspectives, the presence of resistant hypertension and the absence of a nocturnal decrease in blood pressure in obese individuals should prompt the clinician to consider the diagnosis of OSA, especially if clinical symptoms suggestive of OSA (such as poor sleep quality, witnessed apnea, excessive daytime somnolence, and so forth) are also present.

Publication Types:
Review
Review, Tutorial

PMID: 14610096 [PubMed – indexed for MEDLINE]

OSA associated with Heart Attack, October 21, 1999

Obstructive sleep apnea as a risk marker in coronary artery disease.

Schafer H, Koehler U, Ewig S, Hasper E, Tasci S, Luderitz B.

Department of Cardiology and Pulmonary Medicine, University of Bonn, Bonn, Germany. haschaef@mailer.meb.uni-bonn.de

STUDY OBJECTIVES: Obstructive sleep apnea (OSA) is associated with a range of cardiovascular sequelae and increased cardiovascular mortality. The aim of our study was to assess the prevalence of OSA in patients with symptomatic angina and angiographically verified coronary artery disease (CAD). In addition, we analyzed the association of OSA and other coronary risk factors with CAD and myocardial infarction. METHODS: Overnight non-laboratory-monitoring-system recordings for detection of OSA was performed in 223 male patients with angiographically verified CAD and in 66 male patients with exclusion of CAD. A logistic regression analysis was performed to assess associations between risk factors and CAD and myocardial infarction. RESULTS: CAD patients were found to have OSA in 30.5%, whereas OSA was found in control subjects in 19.7%. The mean apnea/hypopnea index (AHI) was significantly higher (p < 0.01) in CAD patients (9.9 +/- 11.8) than in control subjects (6.7 +/- 7.3). Body-mass-index (BMI) was significantly higher in patients with CAD and OSA than in patients with CAD without OSA (28. 1 vs. 26.7 kg/m(2); p < 0.001). No significant difference was found with regard to other risk factors and left ventricular ejection fraction (LVEF) between both groups. Hyperlipidemia (OR 2.3; CI 1. 3-3.9; p < 0.005) and OSA defined as AHI >/=20 (OR 2.0; CI 1.0-3.8, p < 0.05) were independently associated with myocardial infarction. CONCLUSIONS: There is a high prevalence of OSA among patients with angiographically proven CAD. OSA of moderate severity (AHI >/=20) is independently associated with myocardial infarction. Thus, in the care of patients with CAD, particular vigilance for OSA is important. Copyright 2000 S. Karger AG, Basel

PMID: 10702648 [PubMed – indexed for MEDLINE]

For More Information Contact:

Stacey Spillman
225-767-8550
info@lsfbr.org